RxDoctor Payments Data

Joel Campbell

Neurology · Temple, TXNPI 1104245992

Payments from drug & device makers

$13,233in general payments, 2019–2025

Across 648 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$824
  • Novartis$688
  • AstraZeneca$662
  • UCB, Inc.$606
  • Amgen$570
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$290%
  • Food & beverage$13,190100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)79$1,263
Biogen39$824
Novartis40$688
AstraZeneca29$662
UCB, Inc.31$606
Amgen(2 entities)24$570
EMD Serono, Inc.17$481
Sanofi23$474
Acadia Pharmaceuticals Inc25$438
Teva Pharmaceuticals USA, Inc.17$424
Genentech USA, Inc.19$383
Lilly USA, LLC22$377
SK Life Science, Inc.14$348
Upsher-smith Laboratories LLC16$347
Adamas Pharmaceuticals, Inc.15$312
Biohaven Pharmaceuticals, Inc.15$293
Takeda Pharmaceuticals U.S.A., Inc.10$279
Supernus Pharmaceuticals, Inc.17$274
Avanir Pharmaceuticals, Inc.18$267
Sunovion Pharmaceuticals Inc.12$230
Abbott7$219
Grifols USA, LLC10$215
Alnylam Pharmaceuticals Inc.9$204
Eisai Inc.9$191
Merz Pharmaceuticals, LLC7$175
Lundbeck LLC7$158
Neurocrine Biosciences, Inc.6$146
Kyowa Kirin, Inc.6$142
Merz North America, Inc.4$137
Stryker1$134
Argenx US, Inc.4$127
Biohaven Pharmaceutical Holding Company Ltd.6$125
Johnson & Johnson6$119
Livanova USA, Inc.5$118
Boston Scientific5$116
CSL Behring5$105
Tanabe Pharma America, Inc.5$95
Amneal Pharmaceuticals LLC5$90
Sumitomo Pharma America, Inc.4$88
Arbor Pharmaceuticals, Inc.6$82
Greenwich Biosciences, Inc.4$77
Pfizer4$70
Aquestive Therapeutics, Inc.4$65
Bausch Health US, LLC3$64
Currax Pharmaceuticals LLC5$59
GE HealthCare3$48
Aprecia Pharmaceuticals, LLC2$43
Impel Pharmaceuticals Inc.2$43
Promius Pharma LLC2$41
Otsuka America Pharmaceutical, Inc.2$38
Zyla Life Sciences, Inc.2$37
Bristol Myers Squibb2$34
Jazz Pharmaceuticals Inc.2$30
Acorda Therapeutics, Inc1$29
Octapharma USA, Inc.1$29
Banner Life Sciences, LLC1$26
Avion Pharmaceuticals1$23
NS Pharma, Inc.1$22
MDD US Operations, LLC1$19
E.r. Squibb & Sons, L.L.C.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,233 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$64,896
Medicare patients
269
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin14$1,068
Memantine Hcl23$924
Donepezil Hcl40$427
Primidone14$358

Paid to pharmacies, not to this prescriber.

Other neurology in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →